Fig. 7: Lowering FASN protein expression levels improves ATRA therapy in non-APL AML cells.
From: Reducing FASN expression sensitizes acute myeloid leukemia cells to differentiation therapy
A–F MOLM-13 (A, C, E), and OCI-AML2 (B, D, F) cells were treated with ATRA and different concentrations of EGCG (5 µM, 10 µM and 15 µM) for 3 days (n = 3). A–B CD11b surface staining was analyzed by flow cytometry. Box blot represent the median fluorescence intensity (MFI) of CD11b positive cells. C–D Acridine Orange staining. Analysis was performed as in Fig. 6E-G. E–F Total protein extracted from MOLM-13 and OCI-AML2 cells treated as in 7 A/B were subjected to immunoblotting using anti-FASN, anti-pmTOR(Ser2448), anti- pULK1(Ser757), anti-ULK1, anti-pATG13(Ser318) and anti-ATG13 antibodies. Results shown are from at least two biological duplicates.
